Immuno-PET imaging of antibodies and immunoconjugates and uses therefor

Patent Citations (189)

Non-Patent Literature (250)

• Aerts et al., “Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET” J Nucl Med. 50:123-131 ( 2009).Applicant
• Albert et al., “Direct synthesis of [DOTA-DPhe1]-octreotide and [DOTA-DPhe1,Tyr3]-octreotide (SMT487): Two conjugates for systemic delivery of radiotherapeutical nuclides to somatostatin receptor positive tumors in man” Bioorg Med Chem Lett 8:1207-1210 ( 1998).Applicant
• Alley, S.C. et al., “Controlling the location of drug attachment in antibody-drug conjugates, Abstract No. 627, American Association for Cancer Research, 2004 Annual Meeting, Mar. 27-31, 2004 Proceedings of the AACR” 45:52 (2004).Applicant
• Amir et al., “Self-immmolative dendrimers” Angew. Chem. Int. Ed. 42:4494-4499 ( 2003).Applicant
• Amsberry et al., “The lactonization of 2′-hydroxyhydrocinnamic acid amides: A potential prodrug for amines” J Org Chem 55:5867-5877 ( 1990).Applicant
• Arie et al., “Chaperone function of FkpA, a heat shock prolyl isomerase, in the periplasm of Escherichia coli” Mol Microbiol 39(1):199-210 ( 2001).Applicant
• Axworthy et al., “Cure of human carcinoma xenografts by a single dose of pretargeted yttirum-90 with negligible toxicity” P Natl Acad Sci USA 97(4):1802-1807 ( 2000).Applicant
• Baldwin et al., “Monoclonal antibodies in cancer treatment” Lancet 327(8481):603-605 ( 1986).Applicant
• Barbas et al., “Assembly of combinatorial antibody libraries on phage surfaces: the gene III site” P Natl Acad Sci USA 88:7978-7982 (Sep. 1991).Applicant
• Barbas et al., “In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity” P Natl Acad Sci USA 91:3809-3813 (Apr. 1994).Applicant
• Barbas et al., “Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem” P Natl Acad Sci USA 89:4457-4461 (May 1992).Applicant
• Barnes et al., “Methods for growth of cultured cells in serum-free medium” Anal Biochem 102:255-270 ( 1980).Applicant
• Bass et al., “Hormone Phage: An enrichment method for variant proteins with altered binding properties” Proteins: Structure, Function and Genetics 8:309-314 ( 1990).Applicant
• Bhaskar et al., “E-selectin up-regulation allows for targeted drug delivery in prostate cancer” Cancer Res 63:6387-6394 (Oct. 2003).Applicant
• Blend et al., “Labeling anti-HER2/neu monoclonal antibodies with 111In and 90Y using a bifunctional DTPA chelating agent” Cancer Biother Radio 18(3):355-363 ( 2003).Applicant
• Boerner et al., “Production of antigen-specific human monoclonal antibodies from in vitro-primed human splenocytes” J Immunol 147(1):86-95 (Jul. 1, 1991).Applicant
• Borjesson et al., “Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients” Clin Cancer Res 12(7):2133-2140 ( 2006).Applicant
• Bothmann et al., “The periplasmic Escherichia coli peptidylprolyl cis,trans-isomerase FkpA” J Biol Chem 275(22):17100-17105 (Jun. 2000).Applicant
• Brennan et al., “Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments” Science 229(4708):81-83 (Jul. 5, 1985).Applicant
• Briggs et al., “Synthesis of functionalised fluorescent dyes and their coupling to amines and amino acids” J Chem Soc, Perkin Trans 1:1051-1058 ( 1997).Applicant
• Brinkley, M., “A brief survey of methods for preparing protein conjugates with dyes, haptens, and cross-linking reagents” Bioconj Chem 3:2-13 ( 1992).Applicant
• Bruggemann et al., “Designer mice: the production of human antibody repertoires in transgenic animals” Year in Immunology 7:33-40 ( 1993).Applicant
• Cai et al., “PET Imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody” J Nucl Med 48(2):304-310 (Feb. 2007).Applicant
• Camera et al., “Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA)” Eur J Nucl Med 21(7):640-646 ( 1994).Applicant
• Camera et al., “Evaluation of a new DTPA-derivative chelator: Comparative biodistribution and imaging studies of 111in-labeled B3 monoclonal antibody in athymic mice bearing human epidermoid carcinoma xenografts” Nucl Med Biol 20(8):955-962 ( 1993).Applicant
• Capel et al., “Heterogeneity of human IgG Fc receptors” Immunomethods 4:25-34 ( 1994).Applicant
• Carlsson et al., “Protein thiolation and reversible protein—protein conjugation” Biochem J 173:723-737 ( 1978)Applicant
• Carter et al., “High level Escherichia coli expression and production of a bivalent humanized antibody fragment” Bio/Technology 10(2):163-167 (Feb. 1992).Applicant
• Carter et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy” P Natl Acad Sci USA 89:4285-4289 (May 1992).Applicant
• Chari et al., “Immunoconjugates containing novel maytansinoids: Promising anticancer drugs” Cancer Res 52:127-131 ( 1992).Applicant
• Chen et al., “Chaperone activity of DsbC” J Biol Chem 274(28):19601-19605 (Jul. 9, 1999).Applicant
• Chen et al., “Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen” J Mol Biol 293(4):865-881 ( 1999).Applicant
• Chothia et al., “Canonical structures for the hypervariable regions of immunoglobulins” J Mol Biol 196:901-917 ( 1987).Applicant
• Clackson et al., “Making antibody fragments using phage display libraries” Nature 352:624-628 (Aug. 15, 1991).Applicant
• Clynes et al., “Fc receptors are required in passive and active immunity to melanoma” P Natl Acad Sci USA 95:652-656 (Jan. 1998).Applicant
• Collaborative Computational Project, No. 4, “The CCP4 Suite: Programs for Protein Crystallography” Acta Cryst D50:760-763 ( 1994).Applicant
• Crea et al., “Chemical sysnthesis of genes for human insulin” P Natl Acad Sci USA 75:5765-5769 (Dec. 1978).Applicant
• Cree et al., “Methotrexate chemosensitivity by ATP luminescence in human leukemia cell lines and in breast cancer primary cultures: comparison of the TCA-100 assay with a clonogenic assay” Anticancer Drugs 6:398-404 ( 1995).Applicant
• Crouch et al., “The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity” J Immunol Methods 160:81-88 ( 1993).Applicant
• Cunningham et al., “High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis” Science 244:1081-1085 (Jun. 2, 1989).Applicant
• Daeron, “Fc receptor biology” Annu Rev Immunol 15:203-234 ( 1997).Applicant
• de Groot et al., “Cascade-Release Dendrimers' liberate all end groups upon a single triggering event in the dendritic core” Angew. Chem. Int. Ed 42:4490-4494 ( 2003).Applicant
• De Haas et al., “Fcγ receptors of phagocytes” J Lab Clin Med 126:330-341 (Oct. 1995).Applicant
• DeNardo et al., “Comparison of 1,4,7,10-tetraazacyclododecane-N,N′,N′, N′-tetraacetic acid (DOTA)-Peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts” Clin Cancer Res 4:2483-2490 (Oct. 1998).Applicant
• Dennis et al., “Albumin binding as a general strategy for improving the pharmacokinetics of proteins” J Biol Chem 277(38):35035-35043 (Sep. 20, 2002).Applicant
• Dijkers et al., “Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer” Clin Pharmacol Ther 87(5):586-592 (May 2010).Applicant
• Dijkers et al., “Development and characterization of clinical-grade 89Zr-Trastuzumab for HER2/neu ImmunoPET imaging” J Nucl Med 50(6):974-981 (Jun. 2009).Applicant
• Doronina et al., “Development of potent monoclonal antibody auristatin conjugates for cancer therapy” Nat Biotechnol 21(7):778-784 (Jul. 2003).Applicant
• Doronina et al., “Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity” Bioconjug Chem 17(1):114-124 (Jan. 2006).Applicant
• Duncan et al., “The binding site for Clq on IgG” Nature 322:738-740 ( 1988).Applicant
• Eigenbrot et al., “X-Ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison With molecular modeling” J Mol Biol 229:969-995 ( 1993).Applicant
• Embleton et al., “In-cell PCT from mRNA: amplifying and linking the rearranged immunoglobulin heavy and light chain V-genes within single cells” Nucl Acids Res 20(15):3831-3837 ( 1992).Applicant
• Erker et al., “Mono (η-cyclopentadienyl) zirconium complexes: from coordination chemistry to enantioselective catalysis” J Organometallic Chem 400:185-203 ( 1990).Applicant
• Erker et al., “Stereochemistry and catalysis with zirconium complexes” Pure and Applied Chem 63(6):797-806 ( 1991).Applicant
• Fellouse et al., “Synthetic antibodies from a four-amino-acid code: A dominant role for tyrosine in antigen recognition” P Natl Acad Sci USA 101(34):12467-12472 (Aug. 24, 2004).Applicant
• Fishwild et al., “High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice” Nat Biotechnol 14(7):845-851 (Jul. 1996).Applicant
• Fraker et al., “Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril” Biochem Biophys Res Comm 80(4):849-857 (Feb. 28, 1978).Applicant
• Francisco et al., “cAC10-vcMMAE, an anti-CD30 monomethyl auristatin E conjugate with potent and selective antitumor activity” Blood 102(4):1458-1465 (Aug. 15, 2003).Applicant
• Gazzano-Santoro et al., “A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody” J Immunol Methods 202:163-171 ( 1997).Applicant
• “Gemtuzumab Ozogamicin, Treatment of acute myeloid leukemia” Drugs of the Future 25(7):686-692 ( 2000).Applicant
• Geoghegan et al., “Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modification at N-terminal serine” Bioconjugate Chem 3:138-146 ( 1992).Applicant
• Getz et al., “A comparison between the sylfhydryl reductants tris(2-carboxyethyl)phosphine and dithiothreitol for use in protein biochemistry” Anal Biochem 273:73-80 ( 1999).Applicant
• Graham et al., “Characteristics of a human cell line transformed by DNA from human adenovirus type 5” J Gen Virol 36(1):59-72 (Jul. 1977).Applicant
• Gram et al., “In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library” P Natl Acad Sci USA 89:3576-3580 (Apr. 1992).Applicant
• Griffiths et al., “Human anti-self antibodies with high specificity from phage display libraries” EMBO J 12(2):725-734 ( 1993).Applicant
• Gruber et al., “Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli” J Immunol 152:5368-5374 ( 1994).Applicant
• Guss et al., “Structure of the IgG-binding regions of streptococcal protein G” EMBO J 5(7):1567-1575 ( 1986).Applicant
• Guyer et al., “Immunoglobulin binding by mouse intestinal epithelial cell receptors” J Immunol 117(2):587-593 (Aug. 1976).Applicant
• Ham et al., “Media and growth requirements” Method Enzymol 58:44-93 ( 1979).Applicant
• Hamblett et al., (‘Effect of drug loading on the pharmacology, pharmacokinetics and toxicity of an anti-CD30 antibody-drug conjugate, Abstract No. 624, American Association for Cancer Research; 2004 Annual Meeting, Mar. 27-31, 2004, Proceedings of the AACR’45:52 (2004)).Applicant
• Hamblett et al., “Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate” Clin Cancer Res 10:7063-7070 ( 2004).Applicant
• Hamers-Casterman et al., “Naturally occurring antibodies devoid of light chains” Nature 363:446-448 (Jun. 3, 1993).Applicant
• Hara et al., “Overproduction of penicillin-binding protein 7 suppresses thermosensitive growth defect at low osmolarity due to an spr mutation of Escherichia coli” Microbial Drug Resistance 2(1):63-72 ( 1996).Applicant
• Harris, “Production of humanized monoclonal antibodies for in vivo imaging and therapy” Biochem Soc Trans 23(4):1035-1038 (Nov. 1995).Applicant
• Haugland Molecular Probes Handbook of Fluorescent Probes and Research ChemicalsMolecular Probes, Inc., ( 2003).Applicant
• Hawkins et al., “Selection of phage antibodies by binding affinity mimicking affinity maturation” J Mol Biol 226:889-896 ( 1992).Applicant
• Hay et al., “A 2-nitroimidazole carbamate prodrug of 5-amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-YL)carbonyl]-1,2-dihydro-3H-benz[E]indole (amino-seco-DB1-TMI) for use with ADEPT and GDEPT” Bioorg Med Chem Lett 9:2237-2242 ( 1999).Applicant
• Hinman et al., “Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: A novel and potent family of antitumor antibiotics” Cancer Res 53:3336-3342 ( 1993).Applicant
• Hnatowich et al., “The preparation of DTPA-coupled antibodies radiolabeled with metallic radionuclides: an improved method” J Immunol Methods 65:147-157 ( 1983).Applicant
• Hogrefe et al., “A bacteriophage lambda vector for the cloning and expression of immunoglobulin Fab fragments on the surface of filamentous phage” Gene 128:119-126 ( 1993).Applicant
• Holliger et al., “‘Diabodies’: Small bivalent and bispecific antibody fragments” P Natl Acad Sci USA 90:6444-6448 (Jul. 1993).Applicant
• Holliger et al., “Engineered antibody fragments and the rise of single domains” Nat Biotechnol 23(9):1126-36 (Sep. 2005).Applicant
• Hoogenboom et al., “By-passing immunisation. Human antibodies from synthetic repertoires of germline V H gene segments rearranged in vitro” J Mol Biol 227(2):381-388 (Sep. 20, 1992).Applicant
• Hubert et al., “STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors” P Natl Acad Sci USA 96(25):14523-8 ( 1999).Applicant
• Hudson et al., “Engineered antibodies” Nature Medicine 9(1):129-134 (Jan. 2003).Applicant
• Hurle et al., “Protein engineering techniques for antibody humanization” Curr Opin Biotechnol 5:428-433 ( 1994).Applicant
• Idusogie et al., “Mapping of the C1q binding site on Rituxan, a chimeric antibody with a human IgG1 Fc” J Immunol 164:4178-4184 ( 2000).Applicant
• Izard et al., “An improved method for labeling monoclonal antibodies with samarium-153: Use of the bifunctional chelate 2-(p-isothiocyanatobenzyl)-6-methyldiethylenetriamianepentaacetic acid” Biocon Chem 3:346-350 ( 1992).Applicant
• Jackson et al., “In vitro antibody maturation. Improvement of a high affinity, neutralizing antibody against IL-1 β” J Immunol 154(7):3310-3319 ( 1995).Applicant
• Jacobovits et al., “Analysis of homozygous mutant chimeric mice: Deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production” P Natl Acad Sci USA 90:2551-2555 ( 1993).Applicant
• Jakobovits et al., “Germ-line transmission and expression of a human-derived yeast artificial chromosome” Nature 363:255-258 (Mar. 18, 1993).Applicant
• Johnson et al. Methods in Molecular Biology “The Kabat Database and a Bioinformatics Example” Lo, Totowa, NJ:Human Press, vol. 248:11-25 ( 2003).Applicant
• Jones et al., “Materials and Methods/Rapid PCT-cloning of full-length mouse immunoglobulin variable regions” Bio/Technology 9:88-89 (Jan. 1991).Applicant
• Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse” Nature 321:522-525 (May 1986).Applicant
• Junutula et al., “Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs” J Immunol Methods 332:41-52 ( 2008).Applicant
• Junutula et al., “Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index” Nat Biotechnol 26(8):925-32 (Aug. 2008).Applicant
• Kam et al., “Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction” P Natl Acad Sci USA 102(33):11600-11605 (Aug. 2005).Applicant
• Kerr et al., “Listeriolysin O potentiates immunotoxin and bleomycin cytotoxicity” Bioconjugate Chem 8(6):781-784 ( 1997).Applicant
• Kim et al., “Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor” Eur J Immunol 24(10):2429-2434 (Oct. 1994).Applicant
• King et al., “Facile synthesis of maleimide bifunctional linkers” Tetrahedron Lett 43:1987-1990 ( 2002).Applicant
• Kingsburg et al., “A novel peptide delivery system involving peptidase activated prodrugs as antimicrobial agents. Synthesis and biological activity of peptidyl derivatives of 5-fluorouracil” J Med Chem 27:1447-1451 ( 1984).Applicant
• Klussman et al., “Secondary mAb-vcMMAE conjugates are highly sensitive reporters of antibody internalization via the lysosome pathway” Bioconjugate Chem 15:765-773 ( 2004).Applicant
• Kobayashi et al., “Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody” Bioconj Chem 10:103-111 ( 1999).Applicant
• Kobayashi et al., “Evaluation of the in vivo biodistribution of yttium-labeled isomers of CHX-CTPA-conjugated monoclonal antibodies” J. Nucl. Med 39:829-836 ( 1998).Applicant
• Kohler et al., “Continuous cultures of fused cells secreting antibody of predefined specificity” Nature 256:495-497 (Aug. 7, 1975).Applicant
• Kostelny et al., “Formation of a bispecific antibody by the use of leucine zippers” J Immunol 148(5):1547-1553 (Mar. 1, 1992).Applicant
• Kozbor et al., “A human hybrid myeloma for production of human monoclonal antibodies” J Immunol 133(6):3001-3005 (Dec. 1984).Applicant
• Kukis et al., “Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates” J Nucl Med 39:2105-2110 ( 1998).Applicant
• Kunkel et al., “Rapid and Efficient Site-specific Mutagenesis Without Phenotypic Selection” Method Enzymol 154:367-382 ( 1987).Applicant
• Law et al., “CD70 is expressed on renal cell carcinoma and is a potential target for tumor cell elimination by antibody-drug conjugates” P Am Assoc Canc Res 45:144, #625 ( 2004).Applicant
• Lee et al., “Bivalent antibody phage display mimics natural immunoglobulin” J Immunol Methods 284:119-132 ( 2004).Applicant
• Lee et al., “High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold” J Mol Biol 340(5):1073-1093 (Jul. 23, 2004).Applicant
• Lee et al., “Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-GD3 ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts” Cancer Res 61:4474-4482 ( 2001).Applicant
• Lee et al., “The interpretation of protein structures: estimation of static accessibility” J Mol Biol 55(3):379-400 ( 1971).Applicant
• Leung et al., “A method for random mutagenesis of a defined DNA segment using a modified polymerase chain reaction” Technique-A J Methods Cell and Molec Biol 1(1):11-15 ( 1989).Applicant
• Lewis et al., “An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA” Bioconjugate Chem 12:320-324 ( 2001).Applicant
• Lewis et al., “Maleimidocysteineamido-DOTA derivatives: New reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions” Bioconj Chem 9:72-86 ( 1998).Applicant
• Li et al., “Vinyl sulfone bifunctional derivatives of DOTA allow sulfhydryl-or amino-directed coupling to antibodies. Conjugates retain immunoreactivity and have similar biodistributions” Bioconjugate Chem 13:110-115 ( 2002).Applicant
• Lindmark et al., “Binding of immunoglobulins to protein A and immunoglobulin levels in mammalian sera” J Immunol Methods 62:1-13 ( 1983).Applicant
• Liu et al., “Eradication of large colon tumor xenografts by targeted delivery of maytansinoids” P Natl Acad Sci USA 93:8618-8623 (Aug. 1996).Applicant
• Liu, “Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides” Adv Drug Deliver Rev 60:1347-1370 ( 2008).Applicant
• Lode et al., “Targeted therapy with a novel enediyene antibiotic calicheamicin V11 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma” Cancer Res 58:2925-2928 ( 1998).Applicant
• Lonberg et al., “Antigen-specific human antibodies from mice comprising four distinct genetic modifications” Nature 368(6474):856-859 (Apr. 28, 1994).Applicant
• Lonberg et al., “Human antibodies from transgenic mice” Int Rev Immunol 13(1):65-93 ( 1995).Applicant
• Lowman et al., “Mutational analysis and protein engineering of receptor-binding determinants in human placental lactogen” J Biol Chem 266(17):10982-10988 (Jun. 15, 1991).Applicant
• MacCallum et al., “Antibody-antigen interactions: contact analysis and binding site topography” J Mol Biol 262:732-745 ( 1996).Applicant
• Mandler et al., “Immunoconjugates of geldanamycin and Anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines” J National Cancer Institute 92(19):1573-1581 (Oct. 4, 2000).Applicant
• Mandler et al., “Modifications in synthesis strategy improved the yield and efficacy of geldanamycin-herceptin immunoconjugates” Bioconjugate Chem 13:786-791 ( 2002).Applicant
• Mandler et al., “Synthesis and evaluation of antiproliferative activity of a Geldanamycin-Herception™ immunoconjugate” Bioorg Med Chem Lett 10:1025-1028 ( 2000).Applicant
• Mao et al., “EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer” Cancer Res 64:781-788 (Feb. 2004).Applicant
• Mardirossian et al., “The stability in liver homogenates of indium-111 and yttrium-90 attached to antibody via two popular chelators” Nucl Med Biol 20(1):65-74 ( 1993).Applicant
• Marks et al., “By-passing immunization. Human antibodies from V-gene libraries displayed on phage” J Mol Biol 222:581-597 ( 1991).Applicant
• Marks et al., “By-passing immunization: building high affinity human antibodies by chain shuffling” Bio/Technology 10:779-783 (Jul. 1992).Applicant
• Mather, “Establishment and characterization of two distinct mouse testicular epithelia cell lines” Biol Reprod 23:243-252 ( 1980).Applicant
• Matsuda et al., “Structure and physical map of 64 variable segments in the 3′ 0.8-megabase region of the human immunoglobulin heavy-chain locus” Nat Genet 3:88-94 (Jan. 1993).Applicant
• Meares et al., “Conjugation of antibodies with bifunctional chelating agents: Isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions” Anal Biochem 142:68-78 ( 1984).Applicant
• Meares et al., “Macrocyclic chelates of radiometals for diagnosis and therapy” Br J Cancer 62(Suppl X):21-26 ( 1990).Applicant
• Meijs et al., “A facile method for the labeling of proteins with zirconium Isotopes” Nucl Med Biol 23:439-448 ( 1996).Applicant
• Meijs et al., “Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice” J Nucl Med 38(1):112-118 (Jan. 1997).Applicant
• Miederer et al., “Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates” J Nucl Med 45:129-137 ( 2004).Applicant
• Mier et al., “Conjugation of DOTA using isolated phenolic active esters: The labeling and biodistribution of albumin as blood pool marker” Bioconjugate Chem 16:237-240 ( 2005).Applicant
• Miller, “Syntheses and therapeutic potential of hydroxamic acid based siderophores and analogues” Chem Rev 89:1563-1579 ( 1989).Applicant
• Milstein et al., “Hybrid hybridomas and their use in immunohistochemistry” Nature 305:537-540 (Oct. 6, 1983).Applicant
• Miraglia et al., “Homogenous cell- and bead-based assays for high throughput screening using fluorometric microvolume assay technology” J Biomol Screening 4(4):193-204 ( 1999).Applicant
• Mirzadeh et al., “Radiometal labeling of immunoproteins: Covalent linkage of 2-(4-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid ligands to immunoglobulin” Bioconj Chem 1:59-65 ( 1990).Applicant
• Mitchell et al., “Targeting primary human Ph+ B-cell precursor leukemia-engrafted SCID mice using radiolabelied anti-CD19 monoclonal antibodies” J Nucl Med 44:1105-1112 ( 2003).Applicant
• Moore et al., “Apoptosis in CHO cell batch cultures: examination by flow cytometry” Cytotechnology 17:1-11 ( 1995).Applicant
• Morrison et al., “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains” P Natl Acad Sci USA 81:6851-6855 (Nov. 1984).Applicant
• Morrison, “Success in specification” Nature 368(6474):812-813 (Apr. 28, 1994).Applicant
• Mosmann, “Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays” J Immunol Methods 65:55-63 ( 1983).Applicant
• Munson et al., “Ligand: A versatile computerized approach for characterization of ligand-binding systems” Anal Biochem 107:220-239 ( 1980).Applicant
• Nagengast et al., “In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft” J Nucl Med 48:1313-1319 ( 2007).Applicant
• Nakamura et al., “Stereochemistry and total synthesis of dolastatin E” Tetrahedron Letters 36(28):5059-5062 (Jul. 10, 1995).Applicant
• Neuberger, “Generating high-avidity human mabs in mice” Nat Biotechnol 14(7):826 (Jul. 1996).Applicant
• Nicolaou et al., “Calicheamicin θ: A rationally designed molecule with extremely potent and selective DNA cleaving properties and apoptosis Inducing activity.” Agnew Chem Intl ED Engl 33(2):183-186 ( 1994).Applicant
• Niculescu-Duvaz et al., “Antibody-Directed Enzyme Prodrug Therapy (ADEPT): A Review” Adv Drg Del Rev 26:151-172 ( 1997).Applicant
• Nikula et al., “A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies” Nucl Med Biol 22:387-390 ( 1995).Applicant
• Nikula et al., “Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: Pharmacokinetics, bioactivity, toxicity and chemistry” J Nucl Med 40(1):166-176 (Jan. 1999).Applicant
• Oda et al., “Enrichment analysis of phosphorylated proteins as a tool for probing the phosphoproteome” Nat Biotechnol 19:379-382 (Apr. 2001).Applicant
• Okazaki et al., “Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FycγRIIIa” J Molec Biol 336:1239-1249 ( 2004).Applicant
• Orlandi et al., “Cloning immunoglobulin varible domains for expression by the polymerase chain reaction” P Natl Acad Sci USA 86:3833-3837 ( 1989).Applicant
• Orum et al., “Efficient method for constructing comprehensive murine Fab antibody libraries displayed on phage” Nucl Acids Res 21(19):4491-4498 ( 1993).Applicant
• Perk et al., “89Zr as a PET surrogate radioisotope for scouting biodistribution of the gherapeutic radiometals 90Y and 177Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab” J Nucl Med 46(11):1898-1906 (Nov. 2005).Applicant
• Perk et al., Facile radiolabeling of monoclonal antibodies and other proteins with zirconium-89 or gallium-68 for PET imaging using p-isothiocyanatobenzyl-desferrioxamine, Nature Protocols, published online: DOI:10.1038/NPROT.2008.22).Applicant
• Perk et al., “p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging” Eu J Nucl Med Molec Imaging 37:250-259 ( 2010).Applicant
• Perk et al., “Preparation and evaluation of 89Zr-zevalin for monitoring of 90Y-zevalin biodistribution with positron emission tomography” Eur J Nucl Med Mol Imaging 33:1337-1345 ( 2006).Applicant
• Perk et al., “Quantitative PET imaging of met-expressing human cancer xenografts with 89Zr-labeled monoclonal antibody DN30” Eur J Nucl Med Mol Imaging 35:1857-1867 ( 2008).Applicant
• Pettit et al., “Antineoplastic agents 365. Dolastatin 10 SAR probes” Anti-Cancer Drug Design 13:243-277 ( 1998).Applicant
• Pettit et al., “Dolastatins 24: synthesis of (−)-dolastatin 10. 1 X-ray molecular structure of N,N-dimethylvalyl-valyl-dolaisoleuine tert-butyl ester” J Chem Soc Perkins Trans 1:859-863 ( 1996).Applicant
• Pettit et al., “Isolation of dolastatins 10-15 from the marine molus Dolabella auricularia” Tetrahedron 49(41):9151-9170 ( 1993).Applicant
• Pettit et al., “Specific activities of dolastatin 10 and peptide derivatives against Cryptococcus neoformans” Antimicrob Agents and Chemotherapy 42(11):2961-2965 (Nov. 1998).Applicant
• Pettit et al., “The absolute configuration and synthesis of natural (−)-Dolastatin 101” J Am Chem Soc 111:5463-5465 ( 1989).Applicant
• Pettit et al., “The dolastatins; 18: stereospecific synthesis of dolaproine” Synthesis:719-725 (Jun. 1996).Applicant
• Pettit Progress in the Chemistry of Organic Natural Products W. Hertz et al.,SpringerWienNewYork, vol. 70:1-79 ( 1997).Applicant
• Pluckthun, A., “Mono- and bivalent antibody fragments produced in Eschericia coli: engineering, folding and antigen binding” Immunol Reviews(130):151-188 ( 1992).Applicant
• Presta et al., “Humanization of an antibody directed against IgE” J Immunol 151(5):2623-2632 (Sep. 1993).Applicant
• Presta et al., “Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders” Cancer Res 57:4593-4599 (Oct. 1997).Applicant
• Presta, “Antibody engineering” Curr Opin Struct Biol 2:593-596 ( 1992).Applicant
• Proba et al., “Functional antibody single-chain fragments from the cytoplasm of Escherichia coli: influence of thioredoxin reductase (TrxB)” Gene 159:203-207 ( 1995).Applicant
• Ramm et al., “The periplasmic Escherichia coli peptidylprolyl cis,trans isomerase FkpA” J Biol Chem 275(22):17106-17113 (Jun. 2000).Applicant
• Ravetch et al., “Fc receptors” Annu Rev Immunol 9:457-492 ( 1991).Applicant
• Reyes et al., “Expression of human β-interferon cDNA under the control of a thymidine kinase promoter from herpes simplex virus” Nature 297:598-601 (Jun. 17, 1982).Applicant
• Riechmann et al., “Reshaping human antibodies for therapy” Nature 332:323-327 (Mar. 24, 1988).Applicant
• Ripka et al., “Two chinese hamster ovary glycosylation mutants affected in the conversion of GDP-mannose to GDP-fucose” Arch Biochem Biophys 249(2):533-545 (Sep. 1986).Applicant
• Rodeberg et al., “Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-Induced cytotoxic T lymphocytes” Clin Cancer Res 11:4545-4552 ( 2005).Applicant
• Rodrigues et al., “Synthesis and β-lactamase-mediated activation of a cephalosporin-taxol prodrug” Chem Biol 2:223-227 (Apr. 1995).Applicant
• Roselli et al., “In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts” Cancer Biother Radio 14(3):209-220 ( 1999).Applicant
• Rowland et al., “Drug localisation and growth inhibition studies of vindesine-monoclonal anti-CEA conjugates in a human tumour xenograft” Cancer Immunol Immunother 21:183-187 ( 1986).Applicant
• Ruegg et al., “Improved in vivo stability and tumor targeting of Bismuth-labeled antibody” Cancer Res 50:4221-4226 (Jul. 15, 1990).Applicant
• Sastry et al., “Cloning of the immunological repertoire in Escherichia coli for generation of monoclonal catalytic antibodies: construction of a heavy chain variable region-specific cDNA library” P Natl Acad Sci USA 86:5728-5732 (Aug. 1989).Applicant
• Schellenberger et al., “Optical imaging of apoptosis as a biomarker of tumor response to chemotherapy” Neoplasia 5(3):187-192 ( 2003).Applicant
• Schier et al., “Identification of functional and structural amino-acid residues by parsimonious mutagenesis” Gene 169:147-155 ( 1996).Applicant
• Senter et al., “Immunoconjugates comprised of drugs with impaired cellular permeability: A new approach to targeted therapy” P Am Assoc Cancer Res 45:144 ( 2004).Applicant
• Shalaby et al., “Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene” J Exp Med 175:217-225 (Jan. 1992).Applicant
• Shamis et al., “Bioactivation of self-immolative dendritic prodrugs by catalytic antibody 38C2” J Am Chem Soc 126:1726-1731 ( 2004).Applicant
• Sheriff et al., “Redefining the minimal antigen-binding fragment” Nature Struct Biol 3(9):733-736 (Sep. 1996).Applicant
• Shields et al., “High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR” J Biol Chem 276(9):6591-6604 (Mar. 2, 2001).Applicant
• Shively, “18F labeling for immuno-PET: Where speed and contrast meet” J Nucl Med 48(2):170-172 (Feb. 2007).Applicant
• Sias et al., “ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids.” J Immunol Methods 132(1):73-80 ( 1990).Applicant
• Sidhu et al., “Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions” J Mol Biol 338(2):299-310 ( 2004).Applicant
• Simmons et al., “Expression of full-length immunoglobulins in Escherichia coli: Rapid and efficient production of aglycosylated antibodies” J Immunol Methods 263:133-147 ( 2002).Applicant
• Sims et al., “A Humanized CD18 Antibody Can Block Function Without Cell Destruction” J Immunol 151(4):2296-2308 (Aug. 15, 1993).Applicant
• Singh et al., “Labeling of antibodies by in situ modification of thiol groups generated from selenol-catalyzed reduction of native disulfide bonds” Anal Biochem 304(2):147-156 (May 15, 2002).Applicant
• Skerra, A., “Bacterial expression of immunoglobulin fragments” Curr Opin Immunol 5:256-262 ( 1993).Applicant
• Sone et al., “Dolabellin, a cytotoxic bisthiazole metabolite from the sea hare Dolabella auricularia: Structural determination and synthesis” J Org Chem 60:4774-4781 ( 1995).Applicant
• Storm et al., “Effect of small changes in orientation on reaction rate” J Am Chem Soc 94:5815-5825 ( 1972).Applicant
• Sun et al., “Enabling ScFvs as multi-drug carriers: a dendritic approach” Bioorg Med Chem 11:1761-1768 ( 2003).Applicant
• Sun et al., “Syntheses of dendritic linkers containing chlorambucil residues for the preparation of antibody-multidrug immunoconjugates” Bioorg Med Chem Lett 12:2213-2215 ( 2002).Applicant
• Suresh et al., “Bispecific monoclonal antibodies from hybrid hybridomas” Method Enzymol 121:210-228 ( 1986).Applicant
• Swartzman et al., “A homogeneous and multiplexed immunoassay for high-throughput screening using fluorometric microvolume assay technology” Anal Biochem 271:143-151 ( 1999).Applicant
• Syrigos et al., “Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations” Anticancer Res 19:605-614 ( 1999).Applicant
• Szalai et al., “Geometric disassembly of dendrimers: Dendritic amplification” J Am Chem Soc 125:15688-15689 ( 2003).Applicant
• Tait et al., “Improved detection of cell death in vivo with Annexin V radiolabeled by site-specific methods” J Nucl Med 47(9):1546-1553 (Sep. 2006).Applicant
• Thorpe, “Antibody carriers of cytotoxic agents in cancer therapy: a review” Monoclonal Antibodies '84: Biological and Clinical Applications (A Pinchera, G. Doria, F. Dammacco and A. Bargellesi, eds. pp. 475-506 (1985)).Applicant
• Tomlinson et al., “The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops” J Mol Biol 227(3):776-798 (Oct. 5, 1992).Applicant
• Traunecker et al., “Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells” EMBO J 10(12):3655-3659 ( 1991).Applicant
• Tutt et al., “Trispecific F(ab′)3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells” J Immunol 147(1):60-69 (Jul. 1991).Applicant
• Urlaub et al., “Isolation of chinese hamster cell mutants deficient in dihydrofolate reductase activity” P Natl Acad Sci USA 77(7):4216 (Jul. 1980).Applicant
• Van Dongen et al., “Immuno-PET: A navigator in monoclonal antibody development and applications” Oncologist 12:1379-1389 ( 2007).Applicant
• Vaswani et al., “Humanized antibodies as potential therapeutic drugs” Ann Allergy Asthma Immunol 1:105-115 ( 1998).Applicant
• Verel et al., “89Zr Immuno-PET: Comprehensive Procedures for the production of 89Zr-labeled monoclonal antibodies” J Nucl Med 44(8):1271-1281 (Aug. 2003).Applicant
• Verel et al., “Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates” Cancer Biother Radiopharm 18:655-661 ( 2003).Applicant
• Verel et al., “Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice” J Nucl Med 44:1663-1670 ( 2003).Applicant
• Verhoeyen et al., “Reshaping human antibodies: Grafting an antilysozyme activity” Science 239:1534-1536 (Mar. 1988).Applicant
• Vermes et al., “A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labeled Annexin V” J Immunol Methods 184:39-51 ( 1995).Applicant
• Vieira et al., “Production of single-stranded plasmic DNA” Method Enzymol 153:3-11 ( 1987).Applicant
• Vitetta et al., “Redesigning nature's poisons to create anti-tumor reagents” Science 238:1098-1104 ( 1987).Applicant
• Wang et al., “Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry” Protein Sci 14:2436-2446 ( 2005).Applicant
• Ward et al., “Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli” Nature 341:544-546 (Oct. 12, 1989).Applicant
• Waterhouse et al., “Combinatorial infection and in vivo recombination: a strategy for making large phage antibody repertoires” Nucl Acids Res 21(9):2265-2266 ( 1993).Applicant
• Williams et al., “Cloning and sequencing of human immunoglobulin V λ gene segments” Eur J Immunol 23:1456-161 ( 1993).Applicant
• Williams et al., “Numerical selection of optimal tumor imaging agents with application to engineered antibodies” Cancer Biother Radio 16(1):25-35 ( 2001).Applicant
• Winter et al., “Making antibodies by phage display technology” Annu Rev Immunol 12:433-455 ( 1994).Applicant
• Wiseman et al., “Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial” Blood 99(12):4336-4342 ( 2002).Applicant
• Wiseman et al., “Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma” Eur J Nucl Med 27(7):766-777 (Jul. 2000).Applicant
• Witzig et al., “Randomized controlled trial of yttrium-90—labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell Non-Hodgkin's lymphoma” J Clin Oncol 20(10):2453-2463 (May 15, 2002).Applicant
• Witzig et al., “Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma” J Clin Oncol 20(15):3262-3269 (Aug. 1, 2002).Applicant
• Woyke et al., “In vitro activities and postantifungal effects of the potent dolastatin 10 derivative auristatin PHE” Antimicrob Agents Chemother 45(12):3580-3584 (Dec. 2001).Applicant
• Wu et al., “Arming antibodies: prospects and challenges for immunoconjugates” Nat Biotechnol 23(9):1137-1146 (Sep. 23, 2005).Applicant
• Xu et al., “Diversity in the CDR3 region of VH is sufficient for most antibody specificities” Immunity 13:37-45 (Jul. 2000).Applicant
• Yamane-Ohnuki et al., “Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity” Biotechnol Bioeng 87(5):614-622 (Sep. 5, 2004).Applicant
• Yaniv, “Enhancing elements for activation of eukaryotic promoters” Nature 297(6):17-18 (May 1982).Applicant
• Yansura et al., “Nucleotide sequence selection for increased expression of heterologous genes in Escherichia coli”METHODS: A Companion to Methods in Enzymology 4(2):151-158 ( 1992).Applicant
• Yelton et al., “Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis” J Immunol 155:1994-2004 ( 1995).Applicant
• Yu et al., “The biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from Actinosynnema pretiosum” P Natl Acad Sci USA 99(12):7968-7973 (Jun. 11, 2002).Applicant
• Zhang et al., “Epidermal growth factor receptor-related protein inhibits cell growth and induces apoptosis of BxPC3 pancreatic cancer cells” Cancer Res 65(9):3877-3882 (May 1, 2005).Applicant
• Zheng et al., “Caspase-3 controls both cytoplasmic and nuclear events associated with Fas-mediated apoptosis in vivo” P Natl Acad Sci USA 95:13618-13623 (Nov. 1998).Applicant
• Zoller et al., “Oligonucleotide-directed mutagenesis using M13-derived vectors: An efficient and general procedure for the production of point mutations in any fragment of DNA” Nucl Acids Res 10:6487-6504 ( 1987).Applicant
• Boswell et al. et al., “Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view” Nucl Med Biol 34:757-778 ( 2007).Applicant
• Holland et al., “89 Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo” J. Nucl Med 51:1293-1300 ( 2010).Applicant